Department of Pharmaceutical Chemistry, C.L.Baid Metha College of Pharmacy, The Tamilnadu Dr. M.G.R. Medical University, Chennai, India.
Department of Pharmaceutical Analysis, C.L. Baid Metha College of Pharmacy, The Tamilnadu Dr.M.G.R. Medical University, Chennai, India.
Mini Rev Med Chem. 2021;21(16):2361-2388. doi: 10.2174/1389557521666210405161205.
Alzheimer's disease (AD) is a multifactorial neurodegenerative disease, and a drug which targets a single protein would not provide a cure for this disease. Currently available drugs for AD are all palliative rather than curative. FDA approved only five drugs for the treatment of AD, which include tacrine, donepezil, galantamine, rivastigmine, and memantine. Tacrine has been discontinued due to its hepatotoxicity. The lack of therapeutic effectiveness of the single-target drugs and multifactorial etiology of AD have led to the design of multitarget directed ligands for AD.
The researchers in this field are constantly making efforts to develop a drug which may prove to be the exact cure for this disease by exploring the different biological targets associated with AD. The present review comprises various multitarget approaches and tools used for finding out a lead compound or a new drug, which will provide a cure for AD.
We have scrutinized and reviewed 75 research articles published in various peer reviewed journals in the last two decades in the field of multi target directed ligand approaches for the discovery of a new therapeutic agent for AD.
The review highlights the recent advances in the field of AD research and shows that the battle for the discovery of an effective drug for AD is in process and AD still remains an incurable disease for which treatment is just palliative.
The review might be helpful for researchers working on multi target directed ligands against AD.
阿尔茨海默病（AD）是一种多因素神经退行性疾病，针对单一蛋白的药物无法治愈这种疾病。目前用于 AD 的药物都是缓解症状的，而不是治愈性的。FDA 仅批准了五种用于治疗 AD 的药物，包括他克林、多奈哌齐、加兰他敏、利斯的明和美金刚。由于其肝毒性，他克林已被停用。单一靶标药物治疗效果不佳和 AD 的多因素病因导致了针对 AD 的多靶标导向配体的设计。
该领域的研究人员不断努力，通过探索与 AD 相关的不同生物靶标，开发一种可能被证明是治疗这种疾病的确切药物。本综述包括用于寻找先导化合物或新药的各种多靶标方法和工具，这些新药将为 AD 提供治疗方法。
我们仔细审查和回顾了过去二十年在多靶标导向配体方法领域发表的 75 篇同行评议期刊上的研究文章，以发现治疗 AD 的新疗法。
该综述强调了 AD 研究领域的最新进展，并表明发现有效治疗 AD 药物的战斗正在进行中，AD 仍然是一种无法治愈的疾病，其治疗只是缓解症状。
该综述可能有助于从事针对 AD 的多靶标导向配体研究的研究人员。
